LAVA Therapeutics (NASDAQ:LVTX) Major Shareholder Gilde Healthcare Cooperatieve Sells 48,169 Shares of Stock

LAVA Therapeutics N.V. (NASDAQ:LVTX) major shareholder Gilde Healthcare Cooperatieve sold 48,169 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $1.56, for a total value of $75,143.64. Following the sale, the insider owned 5,344,047 shares in the company, valued at $8,336,713.32. The trade was a 0.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Gilde Healthcare Cooperatieve also recently made the following trade(s):

• On Friday, October 10th, Gilde Healthcare Cooperatieve sold 49,869 shares of LAVA Therapeutics stock. The stock was sold at an average price of $1.55, for a total value of $77,296.95.
• On Wednesday, October 8th, Gilde Healthcare Cooperatieve sold 28,954 shares of LAVA Therapeutics stock. The shares were sold at an average price of $1.57, for a total value of $45,457.78.

LAVA Therapeutics Trading Down 0.6%

LAVA Therapeutics stock opened at $1.55 on Friday. LAVA Therapeutics N.V. has a 12 month low of $0.85 and a 12 month high of $2.09. The stock’s 50 day simple moving average is $1.55 and its two-hundred day simple moving average is $1.39. The firm has a market cap of $40.78 million, a PE ratio of -1.48 and a beta of 0.50.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Wednesday, August 13th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). On average, equities research analysts forecast that LAVA Therapeutics N.V. will post -1.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Lepercq De Neuflize Asset Management LLC boosted its position in LAVA Therapeutics by 34.8% during the second quarter. Lepercq De Neuflize Asset Management LLC now owns 31,000 shares of the company’s stock worth $41,000 after purchasing an additional 8,000 shares in the last quarter. BML Capital Management LLC raised its holdings in shares of LAVA Therapeutics by 0.5% in the second quarter. BML Capital Management LLC now owns 1,970,610 shares of the company’s stock worth $2,601,000 after acquiring an additional 10,000 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of LAVA Therapeutics in the first quarter worth $31,000. Finally, Rangeley Capital LLC acquired a new position in shares of LAVA Therapeutics in the second quarter worth $36,000.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Jefferies Financial Group cut LAVA Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $3.00 to $1.50 in a report on Tuesday, August 5th. HC Wainwright reduced their price target on shares of LAVA Therapeutics from $1.50 to $1.24 and set a “neutral” rating on the stock in a research report on Tuesday, August 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LAVA Therapeutics in a research report on Wednesday. Six investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $2.69.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.